Toxicity identification and evaluation of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs)

被引：0
|
作者：
Duan, Heying [1 ]
Girod, Bradley [1 ]
Ninatti, Gaia [1 ]
Ferri, Valentina [1 ]
Kunz, Pamela [2 ]
Fisher, George [3 ]
Moradi, Farshad [1 ]
Davidzon, Guido [4 ]
Franc, Benjamin [1 ]
Iagaru, Andrei [5 ]
Aparici, Carina Mari [1 ]
机构：
[1] Stanford Univ, Div Nucl Med, Radiol, Stanford, CA 94305 USA
[2] Stanford Canc Ctr, Stanford, CA USA
[3] Stanford Univ, Oncol, Stanford, CA 94305 USA
[4] Stanford Univ, Radiol Nucl Med, Stanford, CA 94305 USA
[5] Stanford Univ, Stanford, CA 94305 USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2020年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1442
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [41] Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)
    Schiavo Lena, Marco
    Partelli, Stefano
    Castelli, Paola
    Andreasi, Valentina
    Smart, Chanel Elisha
    Pisa, Eleonora
    Bartolomei, Mirco
    Bertani, Emilio
    Zamboni, Giuseppe
    Falconi, Massimo
    Doglioni, Claudio
    ENDOCRINE PATHOLOGY, 2020, 31 (02) : 119 - 131
  • [42] The outcome of peptide receptor radionuclide therapy (PRRT) in North American patients with advanced well-differentiated neuroendocrine tumors (WD-NETs).
    Naraev, Boris
    Sharma, Nancy
    Engelman, Eric Steven
    Bushnell, David L.
    O'Dorisio, Thomas M.
    Halfdanarson, Thorvardur Ragnar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] Peptide receptor radiotherapy (PRRT) as a potential tool of neoadjuvant therapy in patients with inoperable neuroendocrine tumors (NETs)
    Sowa-Staszczak, Anna
    Pach, Dorota
    Stefanska, Agnieszka
    Tomaszuk, Monika
    Mikolajczak, Renata
    Pawlak, Dariusz
    Trofimiuk, Malgorzata
    Chrzan, Robert
    Hubalewska-Dydejczyk, Alicja
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [44] Can tumor absorbed dose predict response to Peptide Receptor Radionuclide Therapy (PRRT) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)?
    Mileva, M.
    Marin, G.
    Levillain, H.
    van Bogaert, C.
    Critchi, G.
    Marin, C.
    Flamen, P.
    Karfis, I
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 153 - 153
  • [45] Evaluation of interim Dotatate-PET after two cycles of Peptide Receptor Radionuclide Therapy (PRRT) in neuroendocrine tumors (NET)
    Duan, H.
    Song, H.
    Ferri, V
    Fisher, G.
    Shaheen, S.
    Shah, J.
    Nguyen, J.
    Moradi, F.
    Davidzon, G.
    Franc, B.
    Iagaru, A.
    Mari, Aparici C.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 141 - 141
  • [46] Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors
    Kwekkeboom, Dik J.
    Krenning, Eric P.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (01) : 179 - +
  • [47] Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors
    Bodei, Lisa
    Cremonesi, Marta
    Kidd, Mark
    Grana, Chiara M.
    Severi, Stefano
    Modlin, Irvin M.
    Paganelli, Giovanni
    THORACIC SURGERY CLINICS, 2014, 24 (03) : 333 - +
  • [48] Peptide receptor radionuclide therapy (PRRNT) in metastatic neuroendocrine tumors (NETs) arising from the kidney
    Prasad, Vikas
    Kulkarni, Harshad
    Zachert, Carolin
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [49] Assessment of Changes in Mesenteric Fibrosis (MF) after Peptide Receptor Radionuclide Therapy (PRRT) in Midgut Neuroendocrine Tumours (NETs)
    Laskaratos, F.
    Cox, N.
    Woo, W. L.
    Khalifa, M.
    Ewang, M.
    Navalkissoor, S.
    Quigley, A. M.
    Mandair, D.
    Caplin, M.
    Toumpanakis, C.
    NEUROENDOCRINOLOGY, 2019, 108 : 217 - 217
  • [50] Peptide Receptor Radionuclide Therapy (PRRT) in 35 Patients with Metastatic Neuroendocrine Neoplasms (NENs): Overall Response and Toxicity
    Liotsou, T.
    Stefanoyiannis, A.
    Alexandraki, K.
    Koumarianou, A.
    Angelousi, A.
    Kaltsas, G.
    Chatziioannou, S.
    NEUROENDOCRINOLOGY, 2018, 106 : 253 - 253
12345